What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Fixed-dose(s) of PRAX-222 not to exceed the maximum tolerated dose of PRAX-222”In the company’s words, NCT05737784 on ClinicalTrials.gov
- Tested for
- SCN2A-DEE, Epilepsy
- Main trialPhase 1/2
- “The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.”In the company’s words, NCT05737784 on ClinicalTrials.gov
Other drugs for Epilepsy
- BHV-7000Biohaven · Phase 2/3
- ElsunersenPraxis Precision Medicines · Phase 3
- LP352Longboard Pharmaceuticals · Phase 3
- PRAX-562Praxis Precision Medicines · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- EverolimusNovartis · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 Apr 2026 | A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026